Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraperitoneal Nivolumab and Ipilimumab in Gynecologic Cancers
NCT03508570Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2018
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of nivolumab and ipilimumab in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC) and 3 more (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Recommended Phase II Dose at 12 weeks. Started Sep 2018; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)endometrial cancer (EC)Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT03508570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03508570.